Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (221-230 of 324) with videos related to

Pageof 33
Sort By:
The Journal of Infectious Diseases|August 10, 2006
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenzMark A Boyd, Andrew Carr, Kiat Ruxrungtham, et al.
Blood|December 3, 2003
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infectionJohn J Zaunders, Wayne B Dyer, Bin Wang, et al.
Journal of Virology|January 18, 2013
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaquesYin Xu, Chris Weatherall, Michelle Bailey, et al.
BMC Public Health|January 5, 2019
HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits schemeNila J Dharan, Tomas Radovich, Samuel Che, et al.
AIDS Research and Human Retroviruses|December 17, 2019
Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in AustraliaNila J Dharan, Tomas Radovich, Samuel Che, et al.
Plos Pathogens|July 3, 2015
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandGail V Matthews, Anchalee Avihingsanon, Sharon R Lewin, et al.
The Journal of Infectious Diseases|September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trialHelen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2008
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infectionSharon R Lewin, John M Murray, Ajantha Solomon, et al.
Antiviral Therapy|August 5, 2008
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicinAnchalee Avihingsanon, Weerawat Manosuthi, Pacharee Kantipong, et al.
Pageof 33

Showing results (221-230 of 324) with videos related to

Sort By:
Pageof 33
The Journal of Infectious Diseases|August 10, 2006
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenzMark A Boyd, Andrew Carr, Kiat Ruxrungtham, et al.
Blood|December 3, 2003
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infectionJohn J Zaunders, Wayne B Dyer, Bin Wang, et al.
Journal of Virology|January 18, 2013
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaquesYin Xu, Chris Weatherall, Michelle Bailey, et al.
BMC Public Health|January 5, 2019
HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits schemeNila J Dharan, Tomas Radovich, Samuel Che, et al.
AIDS Research and Human Retroviruses|December 17, 2019
Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in AustraliaNila J Dharan, Tomas Radovich, Samuel Che, et al.
Plos Pathogens|July 3, 2015
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandGail V Matthews, Anchalee Avihingsanon, Sharon R Lewin, et al.
The Journal of Infectious Diseases|September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trialHelen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2008
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infectionSharon R Lewin, John M Murray, Ajantha Solomon, et al.
Antiviral Therapy|August 5, 2008
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicinAnchalee Avihingsanon, Weerawat Manosuthi, Pacharee Kantipong, et al.
Pageof 33